产ESBLs阴沟肠杆菌的临床分布及耐药性研究  

Extended Spectrum β-Lactamases Producing Enterobacter cloacae:Its Clinical Distribution and Drug Resistance

作　　者：邵良荣[1] 王国政[1] 孙明中[1] 居会祥[1] 

机构地区：[1]东南大学医学院附属盐城医院,江苏盐城224001

出　　处：《中华医院感染学杂志》2006年第1期105-106,98,共3页Chinese Journal of Nosocomiology

摘　　要：目的 研究产超广谱β-内酰胺酶（ESBLs）阴沟肠杆菌的临床分布及耐药性。方法对我院2002年1月～2004年1月间，确认为阴沟肠杆菌感染及产ESBLs菌株的分布和耐药性进行分析。结果73株阴沟肠杆菌各科室的感染以呼吸科最高，产ESBLs株以痰标本最高，产ESBLs株和非产ESBLs株对亚胺培南、非产ESBLs株对头孢吡肟均未见耐药，产ESBLs株对头孢吡肟部分表现耐药，产ESBLs和非产ESBLs株对头孢曲松、阿莫西林／克拉维酸全部耐药。结论阴沟肠杆菌为医院感染常见病原菌之一，产ESBLs株检出率较高，耐药性增加，临床应依据体外药物敏感试验结果选用抗菌药物，控制耐药菌株的产生。OBJECTIVE To explore the clinical distribution and drug resistance of extended-spectrum β-lactamases （ESBLs） producing Enterobacter cloacae. METHODS The clinical distribution and drug resistance of 73 strains of E. cloacae and ESBLs producing E. cloacae identified in our hospital from Jan 2002 to Jan 2004 were analyzed. RESULTS Among them, the highest detectable rate was in respiratory department and from phlegm specimen. No ESBLs producing E. cloacae and non-ESBLs were resistant to imipenem; no non-ESBLs were resistant to cefepime, but some ESBLs producing E. cloacae was resistant to it; all ESBLs producing E. cloacae and non-ESBLs were resistant to ceftriaxone and amoxicillin/clavulanic acid. CONCLUSIONS E. cloacae is one of the commonest pathogens in nosocomial infection, and ESBLs producing E. cloacae has a high detectable rate, its drug resistance has increased; the clinic should choose antimicrobial agents rationally according to drug sensitive tests in vitro.

关 键 词：阴沟肠杆菌 产超广谱Β-内酰胺酶 临床分布 耐药性 

分 类 号：R969.3[医药卫生—药理学]